This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

ESMO 2017


This event has ended

The European Society for Medical Oncology (ESMO) 2017 Congress took place on 8–12 September 2017 at Conference Center IFEMA, Madrid, Spain.

Boehringer Ingelheim presented an expert roundtable symposium in thoracic cancers on 10 September 2017, 13:00–14:30. A post-meeting delayed webcast of the symposium will be featured here, including panel discussions.

Please check back here next week to view the webcast. 

Symposium agenda

Expert roundtable in thoracic cancers: finding our paradigms in an evolving landscape


Introduction and welcome Prof Silvia Novello (Chair)


Tackling urgent questions in the treatment of adenocarcinoma and squamous cell carcinoma Prof Nicolas Girard and Prof Shiresh Gadgeel


Treating unresectable malignant pleural mesothelioma: current options and future outlook Dr Sanjay Popat 


Summary and meeting close Prof Silvia Novello (Chair)

Download the symposium slide set 

Sequencing Infographic

View this video to see how the landscape for treatment for EGFRM+ NSCLC has evolved, and how insights from afatinib clinical trials can inform treatment sequencing for patients with EGFRM+ NSCLC. The video includes recent data presented at ESMO by Sequist et al.

Rate this

For more information on afatinib clinical trial data, please click here.


  • Saturday 9 September 2017

    Poster discussion session

    • Paediatric neuroectodermal and mesenchymal tumours

      Biomarker prevalence study and Phase I trial of afatinib** in children with malignant tumours

      Nysom et al.

  • Monday 11 September 2017

    Poster discussion session

    • Mesothelioma

      Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib* (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

      Novello et al.

  • Saturday 9 September 2017

    Poster display session

    • NSCLC

      Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program

      Peters et al.


      Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7

      Sequist et al.


      Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: non-interventional LUME-BioNIS study

      Reck et al.

  • Sunday 10 September 2017

    Poster display session

    • HNSCC

      Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): analysis of the LUX-Head & Neck 1 (LHN1) trial

      Machiels et al.

    • Urothelial carcinoma

      Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial

      Font et al.

  • Monday 11 September 2017

    Poster display session

    • NSCLC; breast cancer; solid tumours

      A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC)

      Prat et al.


Prof. Silvia Novello

Prof. Silvia Novello

San Luigi Hospital Orbassano, Italy

Can’t make ESMO 2017? Find out more about upcoming oncology events.

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.


**Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.


Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.